Epidemiology of Health Disparities in Relation to the Biology of Estrogen Receptor–Negative Breast Cancer

Agurs‐Collins, Tanya; Dunn, Barbara K.; Browne, Doris; Johnson, Karen A.; Lubet, Ronald A.

doi:10.1053/j.seminoncol.2010.05.002

Cited by 33 publications

(26 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNBC are believed to account for approximately 15% of breast cancer diagnoses, but approximately 25% of breast cancer-related deaths due to a more aggressive biology (1,2). There is evidence that TNBC is more prevalent among young premenopausal African American women, and women of recent West-African descent (3)(4)(5)(6). Furthermore, gene expression profiling has classified breast cancer into intrinsic subtypes (7,8), among which is the basal-like subtype, representing ER/PRnegative with low HER2-neu-expressing tumors that are characterized as TNBC.…”

Section: Introductionmentioning

confidence: 99%

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Craig

O’Shaughnessy

Kiefer

et al. 2013

Molecular Cancer Therapeutics

206

139

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Craig

O’Shaughnessy

Kiefer

et al. 2013

Molecular Cancer Therapeutics

206

139

View full text Add to dashboard Cite

show abstract

“…It is the second leading cause of cancer death among women, and the latest estimates suggest that over 1,050,000 new breast cancer cases occur worldwide annually. During the past three decades, the mortality of breast cancer among women has decreased significantly but the incidence has doubled (Coughlin et al, 2009;Agurs-Collins et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Association Between XRCC5, 6 and 7 Gene Polymorphisms and the Risk of Breast Cancer: A HuGE Review and Meta-analysis

Zhou

Luan²,

Dong³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: Non-homologous end joining (NHEJ) is a pathway for repairing DNA double-strand breaks. Recent publications indicated that XRCC5, XRCC6 and XRCC7 genes may participate in the pathogenesis of breast cancer. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to investigate associations between XRCC5, XRCC6 and XRCC7 genetic polymorphisms in the NHEJ pathway and breast cancer risk. Methods: Studies focusing on the relationship between genetic polymorphisms in XRCC5, XRCC6 and XRCC7 genes and susceptibility to breast cancer were selected from the Pubmed, Cochrane library, Embase, Web of Science, Springerlink, CNKI and CBM databases. Data were extracted by two independent reviewers. The meta-analysis was performed with Review Manager Version 5.1.6 and STATA Version 12.0 software. The odds ratio (OR) with 95% confidence interval (95%CI) was calculated based on the extracted data. Results: According to the inclusion criteria, we final included seven studies with a total of 2,864 breast cancer cases and 3,060 healthy controls. Meta-analysis results showed that rs3835 (G>A) and rs828907 (G>T) in XRCC5 gene, and rs132793 (G>A) in XRCC6 gene might increase the risk of breast cancer, while rs132788 G>T and rs6002421 (A>G) might be protective factors. However, there was no relationship between XRCC7 genetic polymorphisms and the risk of breast cancer. Conclusion: This meta-analysis suggests that the rs3835 G>A and rs828907 G>T in XRCC5 gene, rs6002421 (A>G), rs132788 (G>T) and rs132793 (G>A) in XRCC6 gene might be risk factors for breast cancer, while the rs132788 (G>T) and rs6002421 (A>G) in XRCC6 gene might be protective.

show abstract

“…The significant decrease in ER staining in the hypoxic group, which is associated with poor prognosis [30], could relate to the fact that HIF-1a induces ER proteasomal degradation in hypoxic microenvironment, and decreases its transcription by reducing the RNApol II recruitment in the promoter region of ESR1 locus [31].…”

Section: Discussionmentioning

confidence: 99%

The glycomic profile of invasive ductal carcinoma of the breast is altered in patients with hypoxic regions: implications for tumor behavior

Rêgo

Filho²,

Cordeiro³

et al. 2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Hypoxic areas in solid tumors are often associated with poor prognosis and resistance to chemotherapy. The aim of the study was to analyze the expression of galectin-1 (Gal-1), galectin-3 (Gal-3), sialic acid and b1-6 branched glycan structures in hypoxic environment of invasive ductal carcinoma (IDC) of the breast. We performed lectin histochemistry with phytohemagglutinin-L (L-PHA) and Sambucus nigra lectin (SNA); and immunohistochemistry for Gal-1, Gal-3, carbonic anhydrase IX, hypoxia-inducible factor, estrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor type-2 for 86 IDC samples. Patients with markers positive for hypoxia were mostly ER-negative (p = 0.003) and presented with more nodal invasion than the non-hypoxic group (p = 0.0439). Concerning the glycobiological aspects, the hypoxic group expressed more of Gal-3 (p = 0.0021) and SNA ligands (p = 0.0498), however, there was no association between lectin-and galectin-staining and clinical and histopathological data. Our results suggest a change in the glycomic profile of patients within hypoxic regions of IDC. However, further studies are needed to evaluate the role of lectin-and galectin-ligands in tumor's hypoxic environment, as well as their potential to be used as therapeutic targets. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 96-103) Key words: breast cancer; IDC; hypoxia; glycomic profile; galectins; lectin ligands; IHC; histochemistry Ĩ ntroduction Breast cancer is the most common cancer among women, accounting for 22% of new cases every year, and the second most common cancer world wide [1]. Moreover, as with most solid tumors, breast cancers often have central regions of hypoxia which are usually peri-necrotic [2]. Cells that survive in this adverse environment are typically resistant to radiotherapy and chemotherapy and differ from cells in areas with adequate blood supply [3,4]. Hypoxia-inducible factor 1a (HIF-1a) is the major modulator of hypoxic condition and is constitutively produced under low-oxygen conditions, which typically occurs at distances greater than 180 μm from blood vessel [5]. HIF-1a affects tumor progression and angiogenesis by modulating the expression of genes involved in the adaptation to oxygen-and nutrient-deficiency, leading to increased cell survival, inhibition of apoptosis and migration [6,7]. Among these genes, carbonic anhydrase IX (CA IX) and glucose transporter 1 (GLUT1) play crucial roles in cellular adaptation, by altering the energy metabolism of neoplastic cells, which begin to show high rates of anaerobic glycolysis [2,[5][6][7]. The change in metabolic profile is followed by altered expression of enzymes involved in aerobic and anaerobic glycolysis, sugar

show abstract

Epidemiology of Health Disparities in Relation to the Biology of Estrogen Receptor–Negative Breast Cancer

Cited by 33 publications

References 118 publications

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Association Between XRCC5, 6 and 7 Gene Polymorphisms and the Risk of Breast Cancer: A HuGE Review and Meta-analysis

The glycomic profile of invasive ductal carcinoma of the breast is altered in patients with hypoxic regions: implications for tumor behavior

Contact Info

Product

Resources

About